Robyn Hunter
Director/Board Member chez TENAX THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Robyn M.
Hunter is an Independent Director at Tenax Therapeutics, Inc. and the Chief Financial Officer at Sotio Biotech AS.
Previously, she served as the Corporate Controller at Indevus Pharmaceuticals, Inc. from 2004 to 2006.
Prior to that, she held the position of Treasurer, Vice President & Accounting Manager at Stackpole Corp.
from 1990 to 2004.
From 2017 to 2022, she was the Chief Financial Officer, Secretary & Treasurer at Fortress Biotech, Inc. Additionally, she has held positions as Secretary at Checkpoint Therapeutics, Inc. and Avenue Therapeutics, Inc., as well as Secretary & Treasurer at Mustang Bio, Inc. She also served as the Chief Financial Officer & Senior Vice President at Schochet Associates, Inc. from 2006 to 2011.
Ms. Hunter obtained her undergraduate degree from Union College (New York) in 1983.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TENAX THERAPEUTICS, INC.
-.--% | 20/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Robyn Hunter
| Sociétés | Poste | Début |
|---|---|---|
| TENAX THERAPEUTICS, INC. | Director/Board Member | 28/01/2022 |
Sotio Biotech AS
 Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Director of Finance/CFO | 01/08/2022 |
Anciens postes connus de Robyn Hunter
| Sociétés | Poste | Fin |
|---|---|---|
| FORTRESS BIOTECH, INC. | Director of Finance/CFO | 16/08/2022 |
| Schochet Associates, Inc. | Director of Finance/CFO | 01/05/2011 |
Indevus Pharmaceuticals, Inc.
 Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Comptroller/Controller/Auditor | 01/01/2006 |
| Stackpole Corp. | Treasurer | 01/01/2004 |
| MUSTANG BIO, INC. | Corporate Secretary | - |
Formation de Robyn Hunter
| Union College (New York) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| TENAX THERAPEUTICS, INC. | Health Technology |
| FORTRESS BIOTECH, INC. | Health Technology |
| CHECKPOINT THERAPEUTICS, INC. | Health Technology |
| AVENUE THERAPEUTICS, INC. | Health Technology |
| MUSTANG BIO, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
| Stackpole Corp. | Producer Manufacturing |
| Schochet Associates, Inc. | |
Sotio Biotech AS
Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Health Technology |
